Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Cabot Wealth Management Inc.

Cabot Wealth Management Inc. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 5.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,496 shares of the company's stock after acquiring an additional 871 shares during the period. Cabot Wealth Management Inc. owned 0.05% of Medpace worth $5,480,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Iron Triangle Partners LP purchased a new stake in Medpace during the third quarter valued at about $64,371,000. Wellington Management Group LLP grew its holdings in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock worth $138,612,000 after purchasing an additional 109,886 shares during the period. DF Dent & Co. Inc. increased its position in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock worth $53,841,000 after purchasing an additional 105,659 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in Medpace in the third quarter valued at approximately $23,321,000. Finally, International Assets Investment Management LLC lifted its position in Medpace by 38,432.9% during the third quarter. International Assets Investment Management LLC now owns 57,414 shares of the company's stock valued at $19,165,000 after buying an additional 57,265 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $381.44.

Remove Ads

Medpace Price Performance

MEDP traded down $1.44 during trading hours on Wednesday, reaching $339.48. 455,800 shares of the stock traded hands, compared to its average volume of 280,857. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The company has a market cap of $10.34 billion, a price-to-earnings ratio of 26.88, a PEG ratio of 3.81 and a beta of 1.36. The firm's fifty day simple moving average is $342.87 and its two-hundred day simple moving average is $346.24.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.